Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Austin, Texas 78759


Purpose:

The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.


Criteria:

Inclusion Criteria: - No clinically significant abnormal findings on physical exam, medical history, or clinical laboratory findings during screening. Exclusion Criteria: - Allergic or adverse responses to zidovudine or any other comparable or similar products. - Participation in clinical trial within 30 days of study initiation. - Positive blood screen for HIV, Hepatitis B and C.


NCT ID:

NCT00602550


Primary Contact:

Principal Investigator
Daniel V Freeland, DO
CEDRA Clinical Research


Backup Contact:

N/A


Location Contact:

Austin, Texas 78759
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.